僵直性脊椎炎治療市場規模、佔有率和成長分析（按治療類型、藥物類型、最終用戶和地區分類）—產業預測（2026-2033 年）

全球僵直性脊椎炎治療市場規模預計在 2024 年達到 33.4 億美元，從 2025 年的 36 億美元成長到 2033 年的 65.7 億美元，在預測期（2026-2033 年）內複合年成長率為 7.8%。

僵直性脊椎炎（AS）在中青年族群的發生率不斷上升，是推動市場成長的主要因素。 AS是一種自體免疫疾病，主要涉及脊椎和骶髂關節，若不及時治療，可導致嚴重的疼痛和功能障礙。遺傳易感性，例如HLA-B27基因，是造成不同地區發病率差異的主要原因，尤其是在歐洲、北美和亞洲部分地區。隨著人們對該疾病認知的提高和診斷技術的改進，AS的早期發現率顯著增加，需要長期有效治療的患者數量也隨之增加。生技藥品，特別是腫瘤壞死因子（TNF）抑制劑和白細胞介素-17（IL-17）抑制劑，已被證實是靶向發炎路徑的有效治療方法。下一代生技藥品的研究進展可望拓展治療選擇，進一步推動投資，並凸顯生技藥品在市場中的重要性。

推動全球僵直性脊椎炎治療市場發展的因素

僵直性脊椎炎在全球的發病率不斷上升，尤其是在年輕族群中，這顯著推動了該市場的擴張。確診病例的增加帶動了對有效治療方案的需求。為此，醫療機構和製藥公司正加大投入，致力於研發創新藥物、先進診斷工具和綜合患者照護方案。這種持續改進治療方案的努力，反映了應對僵直性脊椎炎帶來的不斷變化的醫療挑戰的迫切需要，最終將推動市場成長，並有助於改善患者的治療效果。

限制全球僵直性脊椎炎治療市場的因素

全球僵直性脊椎炎治療市場面臨許多挑戰，尤其是在新興地區。患者和全科醫生對該疾病的認知不足導致診斷延誤，這往往會加速疾病進展並降低治療效果。此外，合格風濕症醫師的短缺以及缺乏全面的早期篩檢措施，加劇了這些問題。因此，這些因素共同阻礙了市場整體成長，必須克服這些障礙，才能改善患者預後並提高僵直性脊椎炎的治療效果。

僵直性脊椎炎治療市場的全球趨勢

全球僵直性脊椎炎治療市場正經歷著向生技藥品的重大轉變，TNF抑制劑和IL-17抑制劑等創新治療方法正在改變治療策略。這一轉變的特點是，醫療服務提供者和患者越來越傾向於選擇這些標靶治療，因為它們具有更高的療效和更長期的疾病控制能力。蓬勃發展的研發環境以及不斷擴大的生物相似藥產品組合進一步推動了市場成長。患者有望獲得更好的生活品質和治療效果，生技藥品很可能成為未來僵直性脊椎炎治療模式的基礎。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究
• 技術分析

全球僵直性脊椎炎治療市場規模（依治療類型分類）及複合年成長率（2026-2033 年）

• 非類固醇消炎劑（NSAIDs）
• 生技藥品（TNF抑制劑、IL-17抑制劑）
• DMARDs（緩解疾病抗風濕藥物）
• 物理治療/運動療法
• 其他

全球僵直性脊椎炎治療市場規模（按藥物類型和複合年成長率分類）（2026-2033 年）

• 原藥
• 學名藥

全球僵直性脊椎炎治療市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院和診所
• 專科診所
• 居家照護

全球僵直性脊椎炎治療市場規模（按地區分類）及複合年成長率（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• AbbVie Inc.（US）
• Novartis AG（Switzerland）
• Johnson & Johnson（US）
• Pfizer Inc.（US）
• Amgen Inc.（US）
• UCB SA（Belgium）
• Bristol-Myers Squibb（US）
• Eli Lilly and Company（US）
• Roche Holding AG（Switzerland）
• Merck & Co., Inc.（US）
• Biogen Inc.（US）
• Celgene Corporation（US）
• Takeda Pharmaceutical Company Limited（Japan）
• Bayer AG（Germany）
• Regeneron Pharmaceuticals（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sandoz International GmbH（Switzerland）
• Lupin Limited（India）
• Mylan NV（US）

結論與建議

Global Ankylosing Spondylitis Treatment Market size was valued at USD 3.34 Billion in 2024 and is poised to grow from USD 3.6 Billion in 2025 to USD 6.57 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The rising incidence of ankylosing spondylitis (AS) among young and middle-aged adults is significantly propelling market growth. AS, an autoimmune condition primarily affecting the spine and sacroiliac joints, can lead to debilitating pain and disability if untreated. Genetic predispositions, such as the HLA-B27 gene, contribute to varying incidence rates across regions, particularly in Europe, North America, and parts of Asia. Enhanced awareness and improved diagnostic procedures are facilitating earlier detection, increasing the patient population that requires effective long-term management. Biologic therapies, particularly tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) blockers, have emerged as effective treatments, specifically targeting inflammatory pathways. Ongoing research into next-generation biologics promises to expand treatment options, further driving investment and emphasizing the role of biologics in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ankylosing Spondylitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ankylosing Spondylitis Treatment Market Segments Analysis

Global Ankylosing Spondylitis Treatment Market is segmented by Treatment Type, Drug Type, End-User and region. Based on Treatment Type, the market is segmented into NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Biologics (TNF Inhibitors, IL-17 Inhibitors), DMARDs (Disease-Modifying Anti-Rheumatic Drugs), Physical Therapy & Exercise and Others. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on End-User, the market is segmented into Hospitals & Clinics, Specialty Clinics and Home Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ankylosing Spondylitis Treatment Market

The rising global incidence of ankylosing spondylitis, especially among younger individuals, significantly contributes to the expansion of this market. As the number of diagnosed cases continues to grow, there is an escalating demand for effective treatment options. In response, healthcare providers and pharmaceutical companies are ramping up investments in the development of innovative drugs, advanced diagnostic tools, and comprehensive patient care approaches. This sustained focus on enhancing therapeutic solutions reflects the urgent need to meet the evolving healthcare challenges posed by ankylosing spondylitis, ultimately driving market growth and fostering improved patient outcomes.

Restraints in the Global Ankylosing Spondylitis Treatment Market

The Global Ankylosing Spondylitis Treatment market faces significant challenges, particularly in emerging regions, where limited awareness among patients and general practitioners contributes to delayed diagnoses. This lag in detection often leads to advanced disease progression and diminished treatment efficacy. Furthermore, a shortage of qualified rheumatologists, coupled with the lack of comprehensive initial screening initiatives, exacerbates these issues. As a result, these factors collectively hinder overall market growth, creating obstacles that must be addressed to improve patient outcomes and enhance the effectiveness of ankylosing spondylitis management.

Market Trends of the Global Ankylosing Spondylitis Treatment Market

The global ankylosing spondylitis treatment market is witnessing a significant shift towards biologics, with innovative therapies like TNF and IL-17 inhibitors transforming management strategies. This evolution is characterized by a growing preference among healthcare providers and patients for these targeted therapies, which offer improved efficacy and long-term disease control. The robust research and development landscape, coupled with an expanding portfolio of biosimilars, is further propelling market growth. Patients can expect enhanced quality of life and better therapeutic outcomes, positioning biologics as the cornerstone of future treatment paradigms in ankylosing spondylitis care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Analysis

Global Ankylosing Spondylitis Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
• Biologics (TNF Inhibitors, IL-17 Inhibitors)
• DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
• Physical Therapy & Exercise
• Others

Global Ankylosing Spondylitis Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Branded Drugs
• Generic Drugs

Global Ankylosing Spondylitis Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Specialty Clinics
• Home Care

Global Ankylosing Spondylitis Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Drug Type, End-User)
  • US
  • Canada
• Europe (Treatment Type, Drug Type, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Type, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Type, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Type, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations